Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Alex R. D. Delbridge, Stephanie Grabow, Andreas Strasser, et al.
Nature reviews. Cancer (2016) Vol. 16, Iss. 2, pp. 99-109
Closed Access | Times Cited: 674

Showing 1-25 of 674 citing articles:

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Lorenzo Galluzzi, Ilio Vitale, Stuart A. Aaronson, et al.
Cell Death and Differentiation (2018) Vol. 25, Iss. 3, pp. 486-541
Open Access | Times Cited: 5295
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale, Elizabeth J. Osterlund, David W. Andrews
Cell Death and Differentiation (2017) Vol. 25, Iss. 1, pp. 65-80
Open Access | Times Cited: 1282
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy, Zoltán Szlávik, James B. Murray, et al.
Nature (2016) Vol. 538, Iss. 7626, pp. 477-482
Closed Access | Times Cited: 946
Apoptosis and Clearance of Apoptotic Cells
Shigekazu Nagata
Annual Review of Immunology (2018) Vol. 36, Iss. 1, pp. 489-517
Closed Access | Times Cited: 880
Bax, Bak and beyond — mitochondrial performance in apoptosis
Aida Peña‐Blanco, Ana J. García‐Sáez
FEBS Journal (2017) Vol. 285, Iss. 3, pp. 416-431
Open Access | Times Cited: 742
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan, Xuan Zhang, Dongwen Lv, et al.
Nature Medicine (2019) Vol. 25, Iss. 12, pp. 1938-1947
Open Access | Times Cited: 495
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
Kyuho Han, Edwin E. Jeng, Gaelen T. Hess, et al.
Nature Biotechnology (2017) Vol. 35, Iss. 5, pp. 463-474
Open Access | Times Cited: 479
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, et al.
Blood (2017) Vol. 130, Iss. 22, pp. 2401-2409
Open Access | Times Cited: 458
Mitochondria as playmakers of apoptosis, autophagy and senescence
Marianna Abate, Agostino Festa, Michela Falco, et al.
Seminars in Cell and Developmental Biology (2019) Vol. 98, pp. 139-153
Closed Access | Times Cited: 452
A fate worse than death: apoptosis as an oncogenic process
Gabriel Ichim, Stephen W. G. Tait
Nature reviews. Cancer (2016) Vol. 16, Iss. 8, pp. 539-548
Open Access | Times Cited: 395
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Sean Caenepeel, Sean P. Brown, Brian Belmontes, et al.
Cancer Discovery (2018) Vol. 8, Iss. 12, pp. 1582-1597
Open Access | Times Cited: 372
Limits to Personalized Cancer Medicine
Ian F. Tannock, John A. Hickman
New England Journal of Medicine (2016) Vol. 375, Iss. 13, pp. 1289-1294
Closed Access | Times Cited: 370
Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities
Ling Li, Shuo Hu, Xiaohong Chen
Biomaterials (2018) Vol. 171, pp. 207-218
Open Access | Times Cited: 345
Targeting apoptotic caspases in cancer
Ashley Boice, Lisa Bouchier‐Hayes
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2020) Vol. 1867, Iss. 6, pp. 118688-118688
Open Access | Times Cited: 328
Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes
Peter J. Thompson, Ajit Shah, Vasilis Ntranos, et al.
Cell Metabolism (2019) Vol. 29, Iss. 5, pp. 1045-1060.e10
Open Access | Times Cited: 284
BCL-2 protein family: attractive targets for cancer therapy
Deeksha Kaloni, Sarah T. Diepstraten, Andreas Strasser, et al.
APOPTOSIS (2022) Vol. 28, Iss. 1-2, pp. 20-38
Open Access | Times Cited: 270
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, et al.
Blood (2017) Vol. 130, Iss. 22, pp. 2392-2400
Open Access | Times Cited: 254
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy
Rongqing Pan, Vivian Ruvolo, Hong Mu, et al.
Cancer Cell (2017) Vol. 32, Iss. 6, pp. 748-760.e6
Open Access | Times Cited: 253
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Christiana M. Neophytou, Ioannis P. Trougakos, Nuray Erin, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4363-4363
Open Access | Times Cited: 237
Combinational strategy for high-performance cancer chemotherapy
Si‐Yong Qin, Yin‐Jia Cheng, Qi Lei, et al.
Biomaterials (2018) Vol. 171, pp. 178-197
Closed Access | Times Cited: 235
Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate
Lei Hu, Meng Chen, Xueran Chen, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 4
Open Access | Times Cited: 226
Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death
Haijiao Lu, Shengzhe Zhang, Jie Wu, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 23, pp. 6066-6077
Open Access | Times Cited: 220
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
Paul Lyons, James E. Peters, Federico Alberici, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 212
Mitochondrial dynamics as regulators of cancer biology
Andrew Trotta, Jerry E. Chipuk
Cellular and Molecular Life Sciences (2017) Vol. 74, Iss. 11, pp. 1999-2017
Open Access | Times Cited: 196
BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini, Glaciano Ribeiro, Jorge Vaz Pinto Neto, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 184
Page 1 - Next Page

Scroll to top